Currently, out of the existing stock ratings of Peter Lawson - 11 which are a Sell (6.18%), 143 which are a Buy (80.34%), 24 which are a Hold (13.48%)

Peter Lawson

Work Performance Price Targets & Ratings Chart

Analyst Peter Lawson works at BARCLAYS and is covering the Healthcare sector with 368 price targets and ratings displayed on 36 stocks. Previously, Peter Lawson worked at TRUIST, MIZUHO.

Peter Lawson's average stock forecast success ratio is 65.81% with an average time for price targets to be met of 208.5 days.

Most recent stock forecast was given on IOVA, Iovance Biotherapeutics at 18-Sep-2023.

Wall Street Analyst Peter Lawson

Analyst best performing recommendations are on XNCR (XENCOR).
The best stock recommendation documented was for MGNX (MACROGENICS) at 3/4/2020. The price target of $8 was fulfilled within 1 day with a profit of $0.5 (5.88%) receiving and performance score of 58.82.

Average potential price target upside

of $102.52 (75.37%) on NLNK.
of $55.48 (73.2%) on LUMO (LUMOS PHARMA).
of $24.85 (16.56%) on ILMN.

AGIO Agios Pharmaceuticals BPMC Blueprint Medicines CLVS Clovis Oncology CTMX CytomX Therapeutics DCPH Deciphera Pharmaceuticals EPZM Epizyme FATE Fate Therapeutics IOVA Iovance Biotherapeutics KPTI Karyopharm Therapeutics KURA Kura Oncology MGNX MacroGenics PRLD Prelude Therapeutics RCUS Arcus Biosciences SNDX Syndax Pharmaceuticals SWTX SpringWorks Therapeutics XNCR Xencor YMAB YmAbs Therapeutics ILMN ADAP Adaptimmune Therapeutics plc FLDM Fluidigm LUMO Lumos Pharma MRTX Mirati Therapeutics NLNK NEXI XON EXAS Exact Sciences IMGN ImmunoGen INCY yte ARVN Arvinas AFMD Affimed N.V CDNA CareDx CRSP CRISPR Therapeutics AG EXEL Exelixis IMMU REPL Replimune Group RLAY Relay Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Kennen Mackay (RBC)